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We assessed the accuracy of yeast bloodstream isolate identification performed over a 1-year period at 10 South Korean hospi-
tals, using the matrix-assisted laser desorption ionization–time of flight (MALDI-TOF)-based Vitek MS system. The overall phe-
notypic misidentification rate was 3.4% (18/533), with considerable variation between hospitals (0.0% to 19.0%), compared to
1.1% (6/533) for the Vitek MS system.
Bloodstream infections (BSIs) caused by yeasts, especially Can-dida species, are associated with a poor prognosis, though
attributable mortality can be limited by prompt, appropriate ad-
ministration of antifungal therapy (1). Rapid and accurate iden-
tification of bloodstream isolates can aid in selection of empirical
antifungal therapy based upon general predictable resistance pro-
files to antifungal agents (2). The Clinical and Laboratory Stan-
dards Institute (CLSI) recently proposed new species-specific
breakpoints for antifungal agents (3), highlighting the importance
of accurate species identification in the clinical laboratory. While
misidentification of yeast species can have profound effects on the
interpretation of antifungal data and the appropriateness of ther-
apeutic decisions (2–4), the accuracy of clinical identifications of
yeast BSIs has not been assessed in a multicenter study.
Matrix-assisted laser desorption ionization–time of flight mass
spectrometry (MALDI-TOF MS) has recently been developed as a
fast, easy-to-use, cost-effective method for yeast identification
(5–8) and may supplant traditional methods of pathogen identi-
fication. Currently, many clinical microbiology laboratories in
South Korea continue to use phenotypic methods for routine
identification of yeasts. In this study, we assessed the accuracy of
phenotypic identification (PI) of yeast BSIs at 10 South Korean
hospitals over a 1-year period, in comparison with the new
MALDI-TOF-based Vitek MS system (bioMérieux, Marcy
l’Etoile, France). To our knowledge, this represents the first na-
tionwide multicenter study of the accuracy of yeast BSI identifica-
tions, as determined using routine clinical practices.
From January to December 2011, nonduplicate yeast isolates
from blood cultures were prospectively collected at 10 university
hospitals (A to J) in South Korea. All isolates were identified by the
participating institutions using routine phenotypic methods;
however, the procedures used varied between hospitals. While
some hospitals used one of the commercial yeast identification
systems (the Vitek 2 system or Vitek 2 YST [bioMérieux] or API
ID 32C [bioMérieux]) only, others used one or two commercial
identification systems, including the Vitek 2 system, the API 20C
(bioMérieux), or the ATB-Fungus III (bioMérieux), with addi-
tional supplemental tests such as the germ tube test or assessment
of the isolate on cornmeal agar or CHROMagar Candida. In total,
533 isolates were submitted to Chonnam National University
Hospital for further MALDI-TOF-based identification, along
with the PI results obtained at each hospital.
All isolates were reidentified using the Vitek MS system, as
described previously (8, 9). Each isolate was prepared by a direct
on-plate extraction method using 70% formic acid. Spectra were
analyzed, and identifications were calculated automatically by the
advanced spectrum classifier algorithm provided by the manufac-
turer. A confidence value of 60 with the unique spectrum of a
single organism indicated good species-level identification. If no
unique identification pattern was found, a list of possible organ-
isms was given as “low discrimination” (confidence value of
60%) or “bad spectrum,” or the strain was determined to be
outside the scope of the database (“no ID”) (10). A repeat testing
with the Vitek MS was performed when “low discrimination,”
“bad spectrum,” or “no ID” data were obtained. PI and Vitek MS
results were compared by chi-square or Fisher’s exact test using
GraphPad Prism 5 with significance defined as P  0.05.
When prior PI results were compared with those obtained us-
ing the Vitek MS system, 499 (93.6%) isolates were in agreement
at the species level; based upon these findings, these identifications
were considered final (7, 8). For the 34 isolates with discordant
results, definitive identification was ascertained through sequenc-
ing of the D1/D2 domain of the large-subunit rRNA gene using
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primer pairs NL1 and NL4 (11). Overall, PI and Vitek MS pro-
duced similar correct identification rates (96.4% and 96.1%, re-
spectively) across all 533 isolates, with misidentification occurring
more frequently by PI than by Vitek MS (3.4% versus 1.1%, P 
0.05) (Table 1). Yeast isolates misidentified by PI included seven
isolates of Candida tropicalis, three of Candida albicans, two of
Pichia fabianii, one of Candida glabrata, and single isolates of five
rare species. These data show that PI methods had frequently pro-
vided inaccurate results for both common and unusual yeast spe-
cies.
Vitek MS correctly identified 96.1% of all yeasts from BSIs.
Fifteen isolates (2.8%) were not identified, and six isolates (1.1%)
were misidentified. This is comparable to a recent multicenter
study evaluating the Vitek MS identification of yeasts, which
showed that 96.1% and 0.6% isolates were either correctly identi-
fied or misidentified, respectively (9). The isolates misidentified
by the Vitek MS in this study included two isolates of C. tropicalis
identified as C. albicans, one isolate of C. albicans identified as C.
glabrata, one isolate of C. glabrata identified as C. tropicalis, one
isolate of P. fabianii identified as Candida boidinii, and one isolate
of Candida orthopsilosis identified as Candida magnoliae. The mis-
identification of two rare species was due to improper database
entries, but the reason for the misidentification of four isolates of
common species is not completely understood. However, it may
be related to the random error associated with the short extraction
method on the plate in the Vitek MS (9), although further data are
needed.
Many users of the MALDI-TOF technology in microbial iden-
tification build in an automatic repeat testing with extraction or
lysis when poor discriminatory or spectral data are obtained. Usu-
ally, this resolves the vast majority of discrepancies, especially with
the more common yeasts or bacteria (10). In our study, Vitek MS
was unable to identify (“low discrimination,” “bad spectrum,” or
“no ID”) 2.8% of all samples (15 isolates). Of these 15 isolates, two
belonging to two species (P. fabianii and Lodderomyces elongispo-
rus) were not included in the database of the Vitek MS or Vitek 2
(bioMérieux) system. However, the remaining 13 were correctly
identified by the repeat testing using Vitek MS, and the overall
number of correctly identified Candida isolates increased from
512 (96.1%) to 525 (98.5%). As all isolates inconclusively identi-
fied by the primary testing method are routinely retested using
other methods, these findings highlight the advantage of MALDI-
TOF-based systems over conventional PI, as retesting is superior
to misidentification (6–8).
In the present study, the misidentification rate by PI varied
considerably between hospitals (0.0% to 19.0%, P  0.05) (Table
2). The overall misidentification rate by PI was 2.2% (11/498) for
four common Candida species, including C. albicans, Candida
parapsilosis, C. tropicalis, and C. glabrata, but 20.0% (7/35) for 13
rare species (P  0.001). The most common species misidentified
TABLE 1 Species identification by routine phenotypic methods at 10 hospitals during a 1-year period and those obtained by Vitek MS for 533


















identification Misidentification No identificationc (%)
C. albicans 210 200 (95.2) 206 (98.1) 3 (1.4) 1 (0.5) 203 (96.7) 1 (0.5) 6 (2.9)d
C. parapsilosis 111 109 (98.2) 111 (100.0) 109 (98.2) 2 (1.8)d
C. tropicalis 96 84 (87.5) 89 (92.7) 7 (7.3) 91 (94.8) 2 (2.1) 3 (3.1)d
C. glabrata 81 79 (97.5) 80 (98.8) 1 (1.2) 79 (97.5) 1 (1.2) 1 (1.2)d
Candida guilliermondii 9 9 (100.0) 9 (100.0) 9 (100.0)
Candida krusei 6 5 (83.3) 6 (100.0) 5 (83.3) 1 (16.7)d
Candida pelliculosa 5 5 (100.0) 5 (100.0) 5 (100.0)
Candida lusitaniae 3 3 (100.0) 3 (100.0) 3 (100.0)
Candida intermedia 2 2 (100.0) 2 (100.0) 2 (100.0)
Saccharomyces cerevisiae 2 1 (50.0) 1 (50.0) 1 (50.0) 2 (100.0)
Pichia fabianiie 2 0 (0.0) 2 (100.0) 1 (50.0) 1 (50.0)
Candida haemulonii 1 1 (100.0) 1 (100.0) 1 (100.0)
Candida lipolytica 1 1 (100.0) 1 (100.0) 1 (100.0)
C. orthopsilosise 1 0 (0.0) 1 (100.0) 1 (100.0)
Candida melibiosica 1 0 (0.0) 1 (100.0) 1 (100.0)
Kodamaea ohmeri 1 0 (0.0) 1 (100.0) 1 (100.0)
Lodderomyces elongisporuse 1 0 (0.0) 1 (100.0) 1 (100.0)
Total 533 499 (93.6) 514 (96.4) 18 (3.4)f 1 (0.2) 512 (96.1) 6 (1.1)f 15 (2.8)d
a Final identification was defined either by matching of results for prior phenotypic identification and Vitek MS or by D1/D2 sequencing.
b Includes identification to the genus level only (one isolate).
c Includes the “low discrimination,” “bad spectrum,” or “no identification” results.
d Thirteen isolates (six C. albicans, two C. parapsilosis, three C. tropicalis, one C. glabrata, and one C. krusei isolate) which had been categorized as “no identification” by the initial
test were correctly identified after repeating the test with the Vitek MS.
e Not included in the database of Vitek MS.
f P  0.05, prior phenotypic identification versus Vitek MS identification.
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by PI were C. tropicalis (n  7) and then C. albicans (n  3), which
may have resulted in inappropriate antifungal therapy. Commer-
cial yeast identification systems such as Vitek 2 have been shown
to be less satisfactory at identifying C. tropicalis (12), while
CHROMagar Candida has been shown to be useful for identifica-
tion of C. albicans and C. tropicalis (13). In this study, the misiden-
tification rate for BSI yeasts of C. albicans and C. tropicalis was 0%
(0/75) in three hospitals (hospitals B, H, and I) which had used
CHROMagar routinely but 4.1% (10/241) in seven other hospi-
tals. Thus, these data support previous findings that the accuracy
of commercial yeast identification systems can be increased if lab-
oratories use supplemental tests (4, 12). In addition, two hospitals
(hospitals I and J), which had smaller total numbers of BSI isolates
than did the other eight hospitals, showed higher misidentifica-
tion rates (9.1% and 19.0%, respectively), suggesting that the hos-
pitals with higher volumes and thus more experience with pheno-
typic testing showed lower misidentification rates.
Clinical laboratories play a key role in the accurate identifica-
tion of yeast BSIs. Our findings show that misidentification rates
by PI for yeasts from BSIs at 10 South Korean hospitals during a
1-year period were higher than those obtained using Vitek MS and
varied considerably among hospitals. We believe that Vitek MS
represents a robust tool to reduce the rate of misidentification
seen with conventional PI methods. This method offers faster and
more reliable identification of yeast isolates, allowing for prompt
and appropriate antifungal therapy for fungemic patients.
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TABLE 2 Misidentification rates for yeast bloodstream isolates among 10 hospitals according to the phenotypic method used
Final identificationa
No. (%) of isolates misidentified/tested at each hospital (main method[s] used for routine identificationb):
A (V2) B (V2, Ch) C (Gt, AT) D (V2) E (V2) F (32C) G (V2) H (V2, Ch) I (V2, Ch) J (Gt, V2) Total
Common four species 3/94 0/77 2/74 1/57 1/45 0/40 1/37 0/35 1/20 2/19 11/498 (2.2)c
C. albicans 1/50 0/30 1/27 0/23 0/16 0/18 1/12 0/17 0/8 0/9 3/210 (1.9)
C. parapsilosis 0/10 0/29 0/10 0/18 0/8 0/11 0/10 0/7 0/6 0/2 0/111 (0.0)
C. tropicalis 2/24 0/13 1/13 1/12 1/8 0/3 0/9 0/3 0/4 2/7 7/96 (7.3)
C. glabrata 0/10 0/5 0/24 0/4 0/13 0/8 0/6 0/8 1/2 0/1 1/81 (1.2)
Other 13 species 0/0 2/8 0/2 0/6 0/5 2/7 0/2 0/1 1/2 2/2 7/35 (20.0)c
Total 3/94 (3.2) 2/85 (2.4) 2/76 (2.6) 1/63 (1.6) 1/50 (2.0) 2/47 (4.3) 1/39 (2.6) 0/36 (0.0) 2/22 (9.1) 4/21 (19.0) 18/533 (3.4)
a Final identification was defined either by matching of results for prior phenotypic identification and Vitek MS or by D1/D2 sequencing.
b V2, Vitek 2 (bioMérieux, Marcy l’Etoile, France); Ch, CHROMagar Candida; AT, ATB-Fungus III (bioMérieux); Gt, germ tube test; 32C, API ID 32C (bioMérieux).
c P  0.001, common four species versus other 13 species.
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